Mark S. Gelder
2022 - Onconova Therapeutics
In 2022, Mark S. Gelder earned a total compensation of $677.6K as Chief Medical Officer at Onconova Therapeutics.
Compensation breakdown
| Bonus | $131,741 |
|---|---|
| Option Awards | $81,589 |
| Salary | $425,000 |
| Stock Awards | $31,850 |
| Other | $7,458 |
| Total | $677,638 |
Gelder received $425K in salary, accounting for 63% of the total pay in 2022.
Gelder also received $131.7K in bonus, $81.6K in option awards, $31.9K in stock awards and $7.5K in other compensation.
Rankings
In 2022, Mark S. Gelder's compensation ranked 3,844th out of 5,760 executives tracked by ExecPay. In other words, Gelder earned more than 33.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,844 out of 5,760 | 33rd |
Division Manufacturing | 2,174 out of 3,136 | 31st |
Major group Chemicals And Allied Products | 1,051 out of 1,422 | 26th |
Industry group Drugs | 987 out of 1,323 | 25th |
Industry Pharmaceutical Preparations | 723 out of 969 | 25th |
Source: SEC filing on June 7, 2023.
Gelder's colleagues
We found two more compensation records of executives who worked with Mark S. Gelder at Onconova Therapeutics in 2022.